Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic and preclinical literature without systematic review methodology.
PubMed 25604547 · doi:10.1007/s00401-015-1386-3
What was done
This narrative review synthesizes roughly 15 years of mechanistic, preclinical, and biomarker research regarding the role of soluble amyloid-beta oligomers (AβOs) in Alzheimer's disease pathogenesis, diagnosis, and therapeutic targeting.
What was found
The abstract presents mechanistic findings without numerical data. It reports that soluble AβOs—rather than insoluble fibrillar deposits in plaques—drive memory loss and key AD neuropathologies. Proposed mechanisms include AβO membrane insertion or binding to synaptic receptors (with over a dozen candidate receptors proposed), causing glutamate receptor hyperactivity, intracellular calcium overload, tau hyperphosphorylation, insulin resistance, oxidative stress, and synapse loss. Specific therapeutic concepts highlighted include CNS insulin signaling enhancers and AβO-specific antibodies, alongside cerebrospinal fluid AβO detection and molecular imaging probes for diagnostics.
Why it matters
This paper outlines the conceptual shift from insoluble amyloid plaques to soluble Aβ oligomers as the primary neurotoxic agents in Alzheimer's disease, arguing for their use as specific targets for early biomarker detection and disease-modifying therapies.
Limits
The abstract provides no quantitative data, confidence intervals, or study counts. As a narrative review, it lacks systematic search criteria and relies substantially on in vitro and animal models where the specific pathogenic oligomer species and definitive receptor targets remain unresolved.
Cited by
- context Approximately 90% of what is known about Alzheimer's disease has been discovered only within the past 15 years.